162 related articles for article (PubMed ID: 11875587)
1. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
Floras JS
Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
[TBL] [Abstract][Full Text] [Related]
2. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
3. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
[TBL] [Abstract][Full Text] [Related]
5. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
Trindade PT; Rouleau JL
Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
[TBL] [Abstract][Full Text] [Related]
6. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
[TBL] [Abstract][Full Text] [Related]
7. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
[TBL] [Abstract][Full Text] [Related]
8. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Nawarskas J; Rajan V; Frishman WH
Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
[TBL] [Abstract][Full Text] [Related]
9. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
10. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
Machowska A; Juszczak K; Novak P; Thor P
Folia Med Cracov; 2009; 50(3-4):35-42. PubMed ID: 21853869
[TBL] [Abstract][Full Text] [Related]
11. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
Vesterqvist O; Reeves RA
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
[TBL] [Abstract][Full Text] [Related]
12. Combined neutral endopeptidase inhibitors.
Cuculi F; Erne P
Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
[TBL] [Abstract][Full Text] [Related]
13. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective effects of vasopeptidase inhibitors.
Lapointe N; Rouleau JL
Can J Cardiol; 2002 Apr; 18(4):415-20. PubMed ID: 11992135
[TBL] [Abstract][Full Text] [Related]
15. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
16. Current role of neprilysin inhibitors in hypertension and heart failure.
von Lueder TG; Atar D; Krum H
Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
[TBL] [Abstract][Full Text] [Related]
17. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
Chen HH; Lainchbury JG; Harty GJ; Burnett JC
Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Maniu CV; Meyer DM; Redfield MM
Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
[TBL] [Abstract][Full Text] [Related]
19. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
Chen HH; Cataliotti A; Burnett JC
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
[TBL] [Abstract][Full Text] [Related]
20. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders.
Tabrizchi R
Drugs; 2003; 63(20):2185-202. PubMed ID: 14498755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
